Dr. Reddy's intros generic Sabril

Dr. Reddy’s Labs is launching vigabatrin tablets in a dosage strength of 500 mg.

The product is the generic of Lundbeck’s Sabril. 

“We are pleased that this product has been designated as a competitive generic therapy by the FDA,” said Marc Kikuchi, CEO of North America Generics at Dr. Reddy’s. “With a CGT designation, we have 180-day CGT exclusivity to market this product.”

The Sabril brand and generic had a market value of approximately $141 million for the most recent 12 months ending in December 2020, according to IQVIA.

Dr. Reddy’s vigabatrin tablets are available in a bottle count size of 100.